跳至主要内容
临床试验/CTRI/2010/091/001389
CTRI/2010/091/001389招募中2 期

Phase-2 comparative clinical trial to assess the efficacy and safety of sodium nitrite inhalation in treatment of secondary pulmonary hypertension & hypoxemic conditions

Defence R&D Organisation0 个研究点目标入组 158 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
158

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • a) Healthy volunteers
  • 1. Healthy Males/females, between 18-45 years ages group
  • 2. On no permanent treatment
  • 3. Suffering from no permanent / recurrent / chronic disease or disability
  • b) Diseased subjects
  • 1. Worked up adult patients with pulmonary hypertension with associated hypoxemia, mild or moderate asthma or COPD or ILD with hypoxemia.
  • 2. Stable treatment and symptoms history
  • 3. Age group: 18-65 years
  • 4. Ambulatory, preferably admitted or confined patients for better follow up
  • 5. Non-critically ill patients
  • 6. No need to stop medication

排除标准

  • a)Healthy volunteers
  • 1. Those who do not sign the ICF
  • 2. Those who have had any medical condition which in the judgement of the investigator may render them inappropriate for participation in the trial or who cannot inhale properly
  • 3. Patients who have received any other investigational drug for the last 1 month.
  • 4. Too low or too high body weight (< 40 kg, > 100 kg)
  • 5. Pregnant & lactating women
  • b) Diseased subjects
  • 1. Patients with prior hypersensitivity to nitrates
  • 2. Patients who are unwilling to give informed consent.
  • 3. Patients receiving oral or systemic nitric acid donors or known to have increased indigenous nitric oxide production within 4 weeks of the start of the study.
  • 4. Patients on continuous oxygen
  • 5. Volunteers with serious or critical illness.
  • 6. Patients who are pregnant, lactating or women of child bearing potential not using medically accepted methods of contraception.
  • 7. Patients with clinically significant renal, respiratory (other than those mentioned), cardiac (including rheumatic or congenital heart disease), gastrointestinal, hepatic, endocrine or hematological disorders.
  • 8. Patients who have any medical condition which in the judgement of the investigator may render them inappropriate for participation in the trial.
  • 9. Patients who have received any other investigational drug for the last 1 month

研究者

发起方
Defence R&amp;D Organisation

相似试验